Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities
AUTOR(ES)
Pimentel, Maria Inês Fernandes, Vasconcellos, Érica de Camargo Ferreira e, Ribeiro, Carla de Oliveira, Lyra, Marcelo Rosandiski, Saheki, Mauricio Naoto, Salgueiro, Mariza de Matos, Antonio, Liliane de Fátima, Schubach, Armando de Oliveira
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
2017-03
RESUMO
Abstract Although New World cutaneous leishmaniasis is not itself a life-threatening disease, its treatment with systemic antimonials can cause toxicity that can be dangerous to some patients. Intralesional meglumine antimoniate provides a viable, less toxic alternative. Herein, we describe an alternative treatment with subcutaneous intralesional injections of meglumine antimoniate into large periarticular lesions of three patients with cutaneous leishmaniasis and comorbidities. This treatment was safe, successful, and well tolerated. This case series suggests that intralesional meglumine antimoniate is an effective therapy for cutaneous leishmaniasis, even with periarticular lesions. This hypothesis should be tested in controlled clinical trials.
Documentos Relacionados
- Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
- Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
- Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
- Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
- In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.